PhRMA President: Overturning Obamacare Will Hurt The Industry

In an interview with the Wall Street Journal on Thursday, the president of the pharmaceutical industry trade group PhRMA, John Castellani, discussed some of the adverse effects the industry would experience if the health care law was struck down. The most disruptive effect, he claimed, would be on generic versions of drugs called “biologics.” The law made it easier for companies to gain approval to produce generic versions of those drugs; Castellani claimed it would be harder to approve those if the law was struck down, and that it would take time for that provision to be reintroduced. Overturning the law would also throw some prescription drug benefits, namely those under Medicare Part D, into question, according to Castellani.

-Zachary Bernstein